Background

Chronic low-grade inflammation in visceral adipose tissue (VAT) represents a critical pathophysiological mechanism underlying age-related metabolic dysfunction. Despite emerging evidence linking senescent macrophage accumulation to inflammatory cascades, targeted molecular interventions remain underdeveloped. Xu et al. demonstrated senescent cell burden correlates with inflammatory markers in metabolic syndrome (Nature Medicine, 2018), while Kirkland et al. validated senolytic approaches in preclinical models (Cell Metabolism, 2017).

Hypothesis

Selective pharmacological elimination of p16INK4a-positive senescent macrophages via dasatinib+quercetin will significantly attenuate pro-inflammatory SASP (senescence-associated secretory phenotype) signaling, reducing IL-6 and TNF-α mediated inflammatory responses in visceral adipose tissue.

Mechanistic Rationale

• Senescent macrophage accumulation drives chronic inflammatory signaling via SASP
• p16INK4a acts as a key molecular sentinel of cellular senescence
• Dasatinib targets tyrosine kinases promoting macrophage senescent cell clearance
• Quercetin provides complementary senolytic and anti-inflammatory mechanisms
• Interruption of NF-κB and JAK-STAT inflammatory pathways

Testable Predictions

1. Reduce p16INK4a-positive macrophage population by ≥40% in VAT (flow cytometry)
2. Decrease serum IL-6 levels by >35% (ELISA, p<0.01)
3. Improve insulin sensitivity with C-statistic >0.75 in intervention group
4. Demonstrate >50% reduction in senescence-associated β-galactosidase positive cells

Limitations

• Potential off-target effects of senolytic compounds
• Limited translatability between preclinical and human models
• Inter-individual variability in senescent cell response

Clinical Significance

This research provides a targeted molecular strategy for mitigating age-related metabolic inflammation by selectively eliminating senescent immune cells, potentially interrupting progression of metabolic dysfunction.